Cegedim H1 2026 slides: Q2 growth accelerates on e-invoicing push

Cegedim reported H1 2026 revenue of €324.8m (+0.7% reported / +0.8% like-for-like) and accelerated growth in Q2 to +2.5% reported (+2.4% like-for-like) after -1.0% in Q1. Business Services rebounded strongly (+5.5% in Q2; €95.7m in H1, +4.2%), helped by momentum ahead of France’s e-invoicing reform starting Sept. 1, 2026, while Cloud & Support fell 16.4% in H1 (to €15.2m). Management maintained full-year 2026 outlook for like-for-like revenue growth above 2% and reiterated an ~10% EBIT growth target, with a stock move of +1.78% to $10.30 on the day.

Analysis

The investable point is not the current revenue print; it is the conversion of a compliance-driven implementation cycle into an annuity-like transaction stream. That usually supports a higher multiple, but only after the market sees that onboarding does not leak into churn, bad pricing, or support-cost blowouts. In the near term, this kind of setup phase often looks better on bookings than on cash, so 2026 can screen as a good year for top-line and a mediocre year for FCF.

The main second-order beneficiary is the company’s compliance stack, while the main losers are legacy domestic software vendors that rely on sticky renewals and manual workflows. The competitive risk is that a regulatory wave attracts too many vendors chasing the same accounts, which compresses pricing right when implementation costs peak. In healthcare software, the bigger signal is that local incumbents are losing the UX war; once a digital workflow standardizes, switching costs can flip from technical to operational, favoring the vendor that owns the daily payment/invoice path.

Consensus likely underweights the timing asymmetry: the stock can rerate before profitability improves, but only if the September rollout converts cleanly and the setup base does not get inflated by one-time implementation labor. Falsifiers are simple: slower-than-expected business-services momentum into Q3, any renewed trust issue in healthcare, or a 2026 cash-flow miss that forces the market to treat the growth as borrowed from 2027. If those do not occur, the move is probably underdone because the market is still valuing this like a slow-growth legacy software name rather than a regulatory monetization story.

Key Decisions for Investors

• Long CGM.PA on pullbacks over the next 1-3 weeks; use a 6-12 month horizon and look for 10-20% upside if the September e-invoicing conversion starts to show up in Q3 run-rate data.
• Pair trade: long CGM.PA / short EWQ for a 3-6 month catalyst window to isolate company-specific regulatory upside while hedging France beta; cut the trade if Q3 business-services growth fails to hold up.
• Do not chase the first post-print pop; wait for Q3 evidence that setup spend is not impairing FCF, because the market may punish a temporary cash trough before it rewards the 2027 run-rate.
• Set an alert for any cybersecurity or client-retention setback in the healthcare-professionals franchise; that would be the fastest way to invalidate the multiple-re-rating thesis.